Thiomersal - Beech Tree Labs
Alternative Names: BTL-TML-COVID; BTL-TML-HSV; BTL-TML001; Thimerosal - Beech Tree LabsLatest Information Update: 06 Jan 2023
At a glance
- Originator Beech Tree Labs
- Class Antifungals; Antiseptics; Antivirals; Benzoates; Heavy metals; Organometallic compounds; Small molecules; Sulfhydryl compounds
- Mechanism of Action Protein biosynthesis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections; Herpes labialis
- Phase I/II Herpes simplex virus infections; Influenza virus infections
Most Recent Events
- 02 Jan 2023 Thiomersal is still in phase II trials for COVID-2019 infections (In adults, In the elderly) in USA (Sublingual) (NCT04522830)
- 09 Mar 2021 Combined efficacy and adverse event data from two phase II trials in Herpes simplex virus infections released by Beech Tree Labs
- 28 Feb 2021 Beech Tree Labs completes a phase II trial in COVID-2019 infections (In adults, In the elderly) in USA (Sublingual) (NCT04522830)